<DOC>
	<DOCNO>NCT00901901</DOCNO>
	<brief_summary>This randomized trial evaluate clinical benefit sorafenib 400 mg twice daily erlotinib 150 mg day versus sorafenib 400 mg twice daily placebo erlotinib daily subject unresectable advanced metastatic Child-Pugh A HCC . Patients candidate potentially curative intervention ( i.e . surgical resection local ablation ) eligible study .</brief_summary>
	<brief_title>Nexavar-Tarceva Combination Therapy First Line Treatment Patients Diagnosed With Hepatocellular Carcinoma</brief_title>
	<detailed_description>European quality life scale ( 5 dimension ) ( EQ-5D )</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients &gt; 18 year age Patients life expectancy least 12 week Patients histological cytologically document HCC Patients must least one tumor lesion meet follow criterion : The lesion accurately measure least one dimension accord response evaluation criterion solid tumor ( RECIST ) The lesion previously treat local therapy Patients ECOG PS ( Eastern Cooperative Oncology Group Performance Status ) 0 1 Cirrhotic status ChildPugh class A . Patients give write informed consent prior study specific screen procedure understand patient right withdraw study time . History cardiac disease : congestive heart failure &gt; New York Heart Association ( NYHA ) class 2 ; active coronary artery disease ( CAD ) ; cardiac arrhythmia require antiarrhythmic therapy beta blocker digoxin ) , uncontrolled hypertension . Myocardial infarction 6 month prior study entry permit . Abnormalities cornea base history ( e.g . dry eye syndrome , Sogren 's syndrome ) include congenital abnormality ( e.g . Fuch 's dystrophy ) , abnormal slitlamp examination use vital dye ( e.g . fluorescein , BengalRose ) , and/or abnormal corneal sensitivity test ( Schirmer test similar tear production test ) . History interstitial lung disease ( ILD ) . Patients clinically significant gastrointestinal bleeding within 30 day prior study entry . Previous treatment yttrium90 spheres Any condition unstable could jeopardize safety patient his/her compliance study . Uncontrolled ascites ( define easily control diuretic treatment )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Sorafenib ( Nexavar )</keyword>
	<keyword>Erlotinib ( Tarceva )</keyword>
	<keyword>First Line</keyword>
	<keyword>HCC</keyword>
</DOC>